<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="4512">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 08, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04453839</url>
  </required_header>
  <id_info>
    <org_study_id>RLF-100_EA-1</org_study_id>
    <nct_id>NCT04453839</nct_id>
  </id_info>
  <brief_title>RLF-100 (Aviptadil) Intermediate Population Expanded Access Protocol (SAMICARE)</brief_title>
  <acronym>SAMICARE</acronym>
  <official_title>RLF-100 (Aviptadil) Intermediate Population Expanded Access Protocol</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>NeuroRx, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Cavendish Impact Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>NeuroRx, Inc.</source>
  <brief_summary>
    <textblock>
      Patients with Critical COVID-19 and respiratory failure who are ineligible for enrollment in&#xD;
      NCT04311697, who live more than 50 miles from an existing collaborating research center, or&#xD;
      who are already hospitalized and cannot safely be transferred to a collaborating research&#xD;
      facility may be considered for expanded access by the sponsor.&#xD;
&#xD;
      Treating physicians must complete FDA Form 3396 and receive a letter of authorization from&#xD;
      NeuroRx, along with local IRB authorization.&#xD;
&#xD;
      Please refer to FDA guidance for Individual Patient Expanded Access&#xD;
      https://www.fda.gov/media/91160/download&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      5. INTRODUCTION&#xD;
&#xD;
      5.1 Executive Summary RLF-100 (aviptadil) is a synthetic form of Vasoactive Intestinal&#xD;
      Polypeptide (VIP), a ubiquitous, naturally synthesized human peptide with extensively&#xD;
      documented anti-inflammatory, anti-cytokine cascade properties. It has been granted FDA Fast&#xD;
      Track Designation for treatment of Critical COVID-19 with Respiratory Failure. A phase 2/3&#xD;
      trial is underway that has passed its first evaluation at 30 patients for safety and&#xD;
      futility. This expanded access protocol is designed to offer access to investigational use of&#xD;
      RLF-100 to patients who do not qualify for inclusion in Protocol RLF-100-001 (NCT04311697)&#xD;
      either on the basis of specific medical exclusions or because there is no accessible study&#xD;
      site available to the prospective participant.&#xD;
&#xD;
      5.2 Definition of Critical COVID-19&#xD;
&#xD;
      In May 2020, FDA defined Critical COVID-19 to be used in clinical trials and disease staging&#xD;
      as follows:&#xD;
&#xD;
      Critical COVID-19&#xD;
&#xD;
        -  Positive testing by standard RT-PCR assay or an equivalent test&#xD;
&#xD;
        -  Evidence of Respiratory Failure based on FDA definition of: need for Endotracheal&#xD;
           intubation and mechanical ventilation, oxygen delivered by high-flow nasal cannula&#xD;
           (heated, humidified, oxygen delivered via reinforced nasal cannula at flow rates &gt; 20&#xD;
           L/min with fraction of delivered oxygen â‰¥ 0.5), noninvasive positive pressure&#xD;
           ventilation, ECMO, or clinical diagnosis of respiratory failure (i.e., clinical need for&#xD;
           one of the preceding therapies, but preceding therapies not able to be administered in&#xD;
           setting of resource limitation)&#xD;
&#xD;
      Acute Lung Injury in COVID-19 is characterized by progressive failure of corporeal&#xD;
      oxygenation, attributed on large part by SARS-CoV-2 infection of Alveolar Type II cells&#xD;
      (Mason 2020). Extensive nonclinical studies document that 70% of VIP in the body binds to&#xD;
      receptors on the Alveolar Type II cell, where VIP is known to block cytokine production and&#xD;
      upregulate production of surfactant.&#xD;
&#xD;
      Severity of COVID is associated with and graded by a progressively worsened state of&#xD;
      oxygenation. This is seen in the PaO2/FIO2 ratio, which reflects the status of oxygenation&#xD;
      for patients on high pressure oxygen and mechanical ventilation. In patients breathing room&#xD;
      air, disease severity is assessed by SpO2. Many patients with Critical COVID meet the&#xD;
      clinical definitions of Acute Respiratory Distress Syndrome (ARDS). However, there is&#xD;
      increasing recognition that respiratory distress in COVID-19 has different characteristics&#xD;
      than ARDS in the setting of bacterial sepsis and other common presentations of ARDS.&#xD;
&#xD;
      The pathologic hallmark of COVID-19 lung injury is diffuse alveolar damage, vascular&#xD;
      endothelium damage, and damage to the surfactant-producing type II cells which results in&#xD;
      loss of the integrity of the alveolar-capillary barrier, transudation of protein-rich fluid&#xD;
      across the barrier, pulmonary edema, and hypoxemia from intrapulmonary shunting. Typically,&#xD;
      patients who have progressed to Critical COVID-19 require care in an intensive care unit&#xD;
      (ICU). The mortality rate is approximately 50%. Deaths usually result from multisystem organ&#xD;
      failure rather than lung failure alone.&#xD;
&#xD;
      5.3 RLF-100 Experimental Therapy in COVID-19&#xD;
&#xD;
      Under this protocol, patients with Critical COVID-19 will be treated with RLF-100 (Aviptadil)&#xD;
      with the aim to support pulmonary alveolar function, combat the cytokine-induced&#xD;
      inflammation, improve blood oxygenation, and reduce mortality.&#xD;
&#xD;
      5.4 Clinical Rationale Given by intravenous infusion in appropriate concentrations,&#xD;
      RLF-100-001 has been shown in clinical trials to have a manageable safety profile with no&#xD;
      observed SAEs to date that would rise to the level of a black box warning.&#xD;
&#xD;
      6. OBJECTIVES&#xD;
&#xD;
      6.1 Primary Objective The primary objective of this study is to measure the effectiveness and&#xD;
      safety of RLF-100 + maximal standard of care (SOC) in treating Critical COVID-19 with&#xD;
      Respiratory Failure.&#xD;
&#xD;
      6.2 Secondary Objective The key secondary objective is to test the hypothesis that RLF-100&#xD;
      improves blood oxygenation as measured by SaO2.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Available</overall_status>
  <study_type>Expanded Access</study_type>
  <expanded_access_info>
    <expanded_access_type_intermediate>Yes</expanded_access_type_intermediate>
  </expanded_access_info>
  <condition>Critical COVID-19 With Respiratory Failure</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>RLF-100 (aviptadil)</intervention_name>
    <description>Patients will be treated with 12 hour infusions of RLF-100 at ascending doses of 50/100/150 pmol/kg/hr on 3 successive days</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Critical COVID-19 with Respiratory Failure&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients who are eligible for enrollment in RLF-100_001 are excluded from this&#xD;
             protocol and live within 50 miles of a study site for NCT04311697 cannot be enrolled&#xD;
             unless already admitted to an ICU and ineligible for transfer&#xD;
&#xD;
          -  Mean Arterial Pressure &lt; 65 mm Hg with use of pressor per ICU protocol&#xD;
&#xD;
          -  Irreversible condition (other than COVID-19) with projected fatal course&#xD;
&#xD;
          -  ECMO&#xD;
&#xD;
          -  Chemotherapy-induced neutropenia (granulocyte count &lt;1000/mm3);&#xD;
&#xD;
          -  Cardiogenic shock; congestive heart failure - NYHA Class 3 or 4;&#xD;
&#xD;
          -  Liquid Diarrhea more than 3x/day; defined as more than 3 non-bloody watery stools&#xD;
             within a 24-hour period, requiring additional fluid and electrolyte supplementation&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Jonathan C Javitt, MD, MPH</last_name>
    <role>Study Chair</role>
    <affiliation>NeuroRx, Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Robert E Besthof, MIM</last_name>
    <phone>+14842546135</phone>
    <email>expandedaccess@neurorxpharma.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Dignity Health-Mercy Gilbert Medical Center</name>
      <address>
        <city>Gilbert</city>
        <state>Arizona</state>
        <zip>85297</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Available</status>
    <contact>
      <last_name>Brian Tiffany</last_name>
      <email>brian.tiffany@dignityhealth.org</email>
    </contact>
    <investigator>
      <last_name>Brian Tiffany</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Honor Health Shea Medical Center</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85260</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Available</status>
    <contact>
      <last_name>Seth Hameesh</last_name>
      <phone>602-327-9097</phone>
      <email>akshaym@email.arizona.edu</email>
    </contact>
    <investigator>
      <last_name>Seth Hameesh</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kaiser Permanente</name>
      <address>
        <city>Baldwin Park</city>
        <state>California</state>
        <zip>91706</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Available</status>
    <contact>
      <last_name>Alice Chang</last_name>
      <phone>626-851-7008</phone>
      <email>Alice.K.Chang@kp.org</email>
    </contact>
    <investigator>
      <last_name>Hooman Mobassery</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of California - Irvine</name>
      <address>
        <city>Irvine</city>
        <state>California</state>
        <zip>92697</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Available</status>
    <contact>
      <last_name>Richard Lee, MD</last_name>
      <email>richaral@hs.uci.edu</email>
    </contact>
    <investigator>
      <last_name>Richard Lee, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Lawnwood Regional Medical Center</name>
      <address>
        <city>Fort Pierce</city>
        <state>Florida</state>
        <zip>34950</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Available</status>
    <contact>
      <last_name>Sherry Nehaul</last_name>
      <phone>772-467-2871</phone>
      <email>sherry.nehaul@healthtrustpg.com</email>
    </contact>
    <investigator>
      <last_name>Berjan Collin</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Lakeland Regional Health</name>
      <address>
        <city>Lakeland</city>
        <state>Florida</state>
        <zip>33805</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Available</status>
    <contact>
      <last_name>Rebecca Rich</last_name>
      <phone>727-743-5316</phone>
      <email>rebecca.rich@mylrh.org</email>
    </contact>
    <investigator>
      <last_name>That Htun</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Miller School of Medicine / University of Miami Medical Center</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Available</status>
    <contact>
      <last_name>Dushyantha Jayaweera, MD</last_name>
      <email>DJayawee@med.miami.edu</email>
    </contact>
    <investigator>
      <last_name>Dushyanatha Jayaweera, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Daniel H Kett, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Daniel D Yeh, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Baycare St. Joseph Hospital</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33607</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Available</status>
    <contact>
      <last_name>Karen Herring</last_name>
      <phone>813-875-9000</phone>
      <phone_ext>280209</phone_ext>
      <email>Karen.Herring@baycare.org</email>
    </contact>
    <investigator>
      <last_name>Michael Alvarez</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Southeast Georgia Health system</name>
      <address>
        <city>Brunswick</city>
        <state>Georgia</state>
        <zip>31520</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Available</status>
    <contact>
      <last_name>Jennifer Boykin</last_name>
      <phone>912-466-2808</phone>
      <email>jboykin@sghs.org</email>
    </contact>
    <investigator>
      <last_name>Stephen Chitty</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Maui Health Systems</name>
      <address>
        <city>Wailuku</city>
        <state>Hawaii</state>
        <zip>96793</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Available</status>
    <contact>
      <last_name>Peter Muthard</last_name>
      <email>peter.d.muthard@kp.org</email>
    </contact>
    <investigator>
      <last_name>Peter Muthard</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St. Anthony Regional Hospital</name>
      <address>
        <city>Carroll</city>
        <state>Iowa</state>
        <zip>51401</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Available</status>
    <investigator>
      <last_name>Kyle Ulveling</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Louisville</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Available</status>
    <contact>
      <last_name>Rainer Lenhardt, MD</last_name>
      <phone>502-562-3000</phone>
      <email>rainer.lenhardt@louisville.edu</email>
    </contact>
    <investigator>
      <last_name>Rainer Lenhardt, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St. Tammany Parish Hospital</name>
      <address>
        <city>Covington</city>
        <state>Louisiana</state>
        <zip>70433</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Available</status>
    <contact>
      <last_name>Amanda Hardage</last_name>
      <phone>985-898-4423</phone>
      <email>ahardage@stph.org</email>
    </contact>
    <investigator>
      <last_name>Ricardo Blanco</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Our Ladies of Lourdes Regional Hospital</name>
      <address>
        <city>Lafayette</city>
        <state>Louisiana</state>
        <zip>70508</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Available</status>
    <investigator>
      <last_name>Mehandi Haran</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St. Joseph Heritage Healthcare</name>
      <address>
        <city>Saint Joseph</city>
        <state>Missouri</state>
        <zip>64506</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Available</status>
    <contact>
      <last_name>Ana Perez</last_name>
      <phone>714-992-3000</phone>
      <phone_ext>3147</phone_ext>
      <email>ana.perez@stjoe.org</email>
    </contact>
    <investigator>
      <last_name>Balakrishan Gautam</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Great Plains Health</name>
      <address>
        <city>North Platte</city>
        <state>Nebraska</state>
        <zip>69101</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Available</status>
    <contact>
      <last_name>Jason North</last_name>
      <phone>308-568-7446</phone>
      <email>northj@gphealth.org</email>
    </contact>
    <investigator>
      <last_name>Eduardo Freitas</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Self Regional Healthcare</name>
      <address>
        <city>Greenwood</city>
        <state>South Carolina</state>
        <zip>29646</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Available</status>
    <contact>
      <last_name>Abigayle Campbell</last_name>
      <email>abigayle.campbell@selfregional.org</email>
    </contact>
    <investigator>
      <last_name>John Tajeda</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hendrick Medical Center</name>
      <address>
        <city>Abilene</city>
        <state>Texas</state>
        <zip>79601</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Available</status>
    <contact>
      <last_name>Greg Perry</last_name>
      <phone>325-428-8325</phone>
      <email>gperry@hendrickhealth.org</email>
    </contact>
    <investigator>
      <last_name>David Green</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Baptist Hospitals of Southeast Texas</name>
      <address>
        <city>Beaumont</city>
        <state>Texas</state>
        <zip>77701-4689</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Available</status>
    <contact>
      <last_name>Paige Austin</last_name>
      <phone>409-212-7244</phone>
      <email>paige.austin@bhset.net</email>
    </contact>
    <investigator>
      <last_name>Qamar Arfeen</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medical City Denton</name>
      <address>
        <city>Denton</city>
        <state>Texas</state>
        <zip>76210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Available</status>
    <contact>
      <last_name>Marilyn Jackson</last_name>
      <phone>940-384-3125</phone>
      <email>marilyn.jackson@healthtrustpg.com</email>
    </contact>
    <investigator>
      <last_name>Vivek Punjabi</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>HR Health Institute for Research &amp; Development</name>
      <address>
        <city>Edinburg</city>
        <state>Texas</state>
        <zip>78539</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Available</status>
    <contact>
      <last_name>Adolfo Kaplan</last_name>
      <phone>956-447-5557</phone>
      <email>akaplan0504@yahoo.com</email>
    </contact>
    <investigator>
      <last_name>Adolfo Kaplan</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Houston Methodist Hospital</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Available</status>
    <contact>
      <last_name>Jihad G Youssef, MD</last_name>
      <phone>713-441-3948</phone>
      <email>jgyoussef@houstonmethodist.org</email>
    </contact>
    <investigator>
      <last_name>Jihad G Youssef, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Memorial Hermann Hospital Houston</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Available</status>
    <contact>
      <last_name>Shivaramaiah Shashikumar</last_name>
      <email>shashimandya@hotmail.com</email>
    </contact>
    <investigator>
      <last_name>Shivaramaiah Shashikumar</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medical City McKinney</name>
      <address>
        <city>McKinney</city>
        <state>Texas</state>
        <zip>75609</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Available</status>
    <contact>
      <last_name>Angela Trickey</last_name>
      <email>Angela.Trickey@MedicalCityHealth.com</email>
    </contact>
    <investigator>
      <last_name>Daniella Thompson</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.authorea.com/users/321659/articles/472151-vasoactive-intestinal-peptide-treats-respiratory-failure-in-covid-19-by-rescuing-the-alveolar-type-ii-cell?commit=ba802d4208d7adca1a837edc0a29da7ee4b95e20</url>
    <description>Javitt: Vasoactive Intestinal Peptide treats Respiratory Failure in COVID-19 by rescuing the Alveolar Type II cell</description>
  </link>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>June 27, 2020</study_first_submitted>
  <study_first_submitted_qc>June 30, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">July 1, 2020</study_first_posted>
  <last_update_submitted>December 9, 2020</last_update_submitted>
  <last_update_submitted_qc>December 9, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 10, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Respiratory Insufficiency</mesh_term>
  </condition_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>August 15, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/39/NCT04453839/Prot_001.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Informed Consent Form</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>October 19, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/39/NCT04453839/ICF_002.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

